• ̍̍ CSE: BRAX
  • ̍̍ OTC: BRAXF
  • ̍̍ FWB: 4960

Clinical Ketamine Treatment

November 29, 2022

Braxia Scientific Reports Q2 2023 Financial Results; Focused on Growing Clinic and Telemedicine Delivery of Novel Mental Health Treatments in North America

Braxia Health clinic ketamine treatments up 34.5% YoY in Q2 2023 and revenue up 18% YoY Expanded clinic capacity with new, state-of-the-art clinic opened in Ottawa Closed acquisition of KetaMD and launched new ketamine telemedicine platform in Florida TORONTO, ONTARIO November 29, 2022 – Braxia Scientific Corp. (“Braxia Scientific”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, today announced the filing of its financial statements and management discussion and analysis for the second quarter ended September 30, 2022. Complete financial statements along with related management discussion and analysis can be found in the System for Electronic Document Analysis and Retrieval (SEDAR), the electronic filing system for the disclosure documents of issuers across Canada, at www.SEDAR.com. “We are executing on our vision to increase...